Results 181 to 190 of about 80,637 (252)

Reflex Syncope With Complete Heart Block Triggered by Swallowing in a Patient on Immune Checkpoint Inhibitor Therapy

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) are now standard of care for most advanced solid tumors. While effective, they are associated with immune‐related adverse events (irAEs), including rare autonomic complications. We present a patient with metastatic lung adenocarcinoma receiving nivolumab and ipilimumab who developed reflex syncope with ...
Ashley Bouzon, Michael Oropesa, Bardia Adibmoradi, Daniel Weitz   +3 more
wiley   +1 more source

Successful Combination Immunotherapy for Postoperative Recurrence of Esophageal Cancer Following Prior Immune Checkpoint Inhibitor Treatment: A Case Report. [PDF]

Surg Case Rep
Sakada R, Kawazoe T, Natsugoe K, Shin Y, Imoto Y, Harima T, Nambara S, Tsuda Y, Nakanoko T, Ando K, Oki E, Yoshizumi T.   +11 more
europepmc   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

International Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden, Tamara J. Huizer, Ben M. Eyck, Ate van der Gaast, Leni van Doorn, Marjolein Y. V. Homs, J. Jan B. van Lanschot, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Bas P. L. Wijnhoven, Bianca Mostert, Sjoerd M. Lagarde   +12 more
wiley   +1 more source

Immune effector cell‐associated neurotoxicity syndrome (ICANS) during tebentafusp in metastatic uveal melanoma

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Laura Schreieder, Laura Jockel, Veronika Zenderowski, Ralf A. Linker, Sebastian Haferkamp, Elisabeth Bumes, Peter Hau, Konstantin Drexler   +7 more
wiley   +1 more source

The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta‐Analysis

International Journal of Cancer, Volume 159, Issue 9, Page 2262-2277, 1 November 2026.
Currently, there are at least 30 ongoing clinical trials in the enrollment phase to evaluate adding concurrent ICIs to the PACIFIC regimen for a variety of solid tumors. Considering the lack of head‐to‐head comparative studies, this meta‐analysis aims to investigate the differences in efficacy between adding and not adding concurrent ICIs to CRT ...
Xu Tong, Zhenting Liu, Xiaoxiang Zhou, Nan Bi, Yibo Gao   +4 more
wiley   +1 more source

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies. [PDF]

Front Cardiovasc Med
Chattopadhyay A, Dosunmu AO, Reddy D, Dharma S, Panchal K, Kwartler CS, Milewicz DM.   +6 more
europepmc   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Editorial Comment to Real-World Outcomes and Prognostic Factors of Immune Checkpoint Inhibitor Rechallenge for Metastatic Renal Cell Carcinoma: A Multicenter Study. [PDF]

Int J Urol
Okumi M.
europepmc   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, Volume 159, Issue 8, Page 1962-1973, 15 October 2026.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

Association of probiotic use with nivolumab efficacy in gastric cancer patients on gastric acid suppressants. [PDF]

iScience
Yamaguchi M, Uozumi R, Eto T, Fujimoto A, Iihara H, Hatakeyama T, Higuchi A, Maehara Y, Fujii H, Tamaki S, Kawazoe H, Ohtani H.   +11 more
europepmc   +1 more source